Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2021 3
2022 7
2023 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

10 results

Results by year

Filters applied: . Clear all
Page 1
Covid-19 vaccines and variants of concern: A review.
Hadj Hassine I. Hadj Hassine I. Rev Med Virol. 2022 Jul;32(4):e2313. doi: 10.1002/rmv.2313. Epub 2021 Nov 9. Rev Med Virol. 2022. PMID: 34755408 Free PMC article. Review.
Promising Covid-19 vaccines such as WIBP-CorV, AD5-nCOV, ZyCoV-D, CVnCoV, EpiVacCorona and ZF2001 have advanced to clinical studies. This review describes the most relevant mutations in the SARS-CoV-2 spike protein, discusses VE against VOCs, presents rare adverse events a …
Promising Covid-19 vaccines such as WIBP-CorV, AD5-nCOV, ZyCoV-D, CVnCoV, EpiVacCorona and ZF2001 have advanced to clinical studies. …
Antimicrobial Activity of the Serum before and after Vaccination with EpiVacCorona.
Arzumanyan VG, Bystritskaya EP, Kolyganova TI, Iksanova AM, Samoilikov PV, Konanykhina SY, Vartanova AA, Svitich OA. Arzumanyan VG, et al. Bull Exp Biol Med. 2022 Jul;173(3):354-360. doi: 10.1007/s10517-022-05548-6. Epub 2022 Jul 19. Bull Exp Biol Med. 2022. PMID: 35852689 Free PMC article.
We evaluated the effect of vaccination with anti-COVID-19 vaccine EpiVacCorona on serum antimicrobial activity, formation of specific IgG antibodies, and expression of some antimicrobial peptides. ...
We evaluated the effect of vaccination with anti-COVID-19 vaccine EpiVacCorona on serum antimicrobial activity, formation of specific …
Gam-COVID-Vac, EpiVacCorona, and CoviVac effectiveness against lung injury during Delta and Omicron variant surges in St. Petersburg, Russia: a test-negative case-control study.
Barchuk A, Bulina A, Cherkashin M, Berezina N, Rakova T, Kuplevatskaya D, Skougarevskiy D, Okhotin A. Barchuk A, et al. Respir Res. 2022 Oct 10;23(1):276. doi: 10.1186/s12931-022-02206-3. Respir Res. 2022. PMID: 36217139 Free PMC article. Clinical Trial.
The adjusted for age, sex and triage centre VE estimates against any lung injury were 56% (95% confidence interval 54-59) for two-dose Gam-COVID-Vac (Sputnik V), 71% (68-74) for three-dose Gam-COVID-Vac (booster), 2% (-27 to 24) for EpiVacCorona, and 46% (37-53) for CoviVa …
The adjusted for age, sex and triage centre VE estimates against any lung injury were 56% (95% confidence interval 54-59) for two-dose Gam-C …
Assessment of Safety and Prophylactic Efficacy of the EpiVacCorona Peptide Vaccine for COVID-19 Prevention (Phase III).
Ryzhikov AB, Ryzhikov EA, Bogryantseva MP, Usova SV, Nechaeva EA, Danilenko ED, Pyankov SA, Gudymo AS, Moiseeva AA, Onkhonova GS, Pyankov OV, Sleptsova ES, Lomakin NV, Vasilyeva VS, Tulikov MV, Gusarov VG, Pulin AA, Balalaeva MA, Erofeeva SB, Terpigorev SA, Rychkova OA, Petrov IM, Delian VY, Rafalskiy VV, Tyranovets SV, Gavrilova EV, Maksyutov RA. Ryzhikov AB, et al. Vaccines (Basel). 2023 May 18;11(5):998. doi: 10.3390/vaccines11050998. Vaccines (Basel). 2023. PMID: 37243102 Free PMC article.
An early clinical trial (Phase I-II) demonstrated that the EpiVacCorona vaccine is a safe product. The "Multicenter double-blind, placebo-controlled, comparative, randomized trial to assess the tolerability, safety, immunogenicity and prophylactic efficacy of the EpiVac …
An early clinical trial (Phase I-II) demonstrated that the EpiVacCorona vaccine is a safe product. The "Multicenter double-blind, pla …
Retrospective Cohort Study of the Effectiveness of the Sputnik V and EpiVacCorona Vaccines against the SARS-CoV-2 Delta Variant in Moscow (June-July 2021).
Matveeva O, Ershov A. Matveeva O, et al. Vaccines (Basel). 2022 Jun 21;10(7):984. doi: 10.3390/vaccines10070984. Vaccines (Basel). 2022. PMID: 35891148 Free PMC article.
The goal of this study was to evaluate the epidemiological effectiveness of the Sputnik V and EpiVacCorona vaccines against COVID-19. This work is a retrospective cohort study of COVID-19 patients. ...The estimated protection against a severe form of the disease in the 18- …
The goal of this study was to evaluate the epidemiological effectiveness of the Sputnik V and EpiVacCorona vaccines against COVID-19. …
Insight into the Advances in Clinical Trials of SARS-CoV-2 Vaccines.
Basheeruddin Asdaq SM, Jomah S, Rabbani SI, Alamri AM, Salem Alshammari SK, Duwaidi BS, Alshammari MS, Alamri AS, Alsanie WF, Alhomrani M, Sreeharsha N, Imran M. Basheeruddin Asdaq SM, et al. Can J Infect Dis Med Microbiol. 2022 Feb 9;2022:6913772. doi: 10.1155/2022/6913772. eCollection 2022. Can J Infect Dis Med Microbiol. 2022. PMID: 35186175 Free PMC article. Review.
Among them are BioNTech and Moderna vaccines (mRNA based); ChAdOx1, Gam-COVID-Vac, Janssen vaccines (vector-based); CoronaVac, COVAXIN (virus inactivated); and EpiVacCorona vaccine (viral peptide). Mixtures of vaccines are also being tested to evaluate their efficacy again …
Among them are BioNTech and Moderna vaccines (mRNA based); ChAdOx1, Gam-COVID-Vac, Janssen vaccines (vector-based); CoronaVac, COVAXIN (viru …
Mini-Review Discussing the Reliability and Efficiency of COVID-19 Vaccines.
Doroftei B, Ciobica A, Ilie OD, Maftei R, Ilea C. Doroftei B, et al. Diagnostics (Basel). 2021 Mar 24;11(4):579. doi: 10.3390/diagnostics11040579. Diagnostics (Basel). 2021. PMID: 33804914 Free PMC article. Review.
The remaining five (Convidicea (AD5-nCOV); Johnson & Johnson (Ad26.COV2.S); Sinopharm (BBIBP-CorV); Covaxin (BBV152), and Sinovac (CoronaVac)) were discussed based on their immunogenicity, and safety reported by the recipients since only phases 1 and 2 were conducted without …
The remaining five (Convidicea (AD5-nCOV); Johnson & Johnson (Ad26.COV2.S); Sinopharm (BBIBP-CorV); Covaxin (BBV152), and Sinovac (Coron …
COVID-19 vaccines effectiveness against symptomatic SARS-CoV-2 during Delta variant surge: a preliminary assessment from a case-control study in St. Petersburg, Russia.
Barchuk A, Bulina A, Cherkashin M, Berezina N, Rakova T, Kuplevatskaya D, Stanevich O, Skougarevskiy D, Okhotin A. Barchuk A, et al. BMC Public Health. 2022 Sep 22;22(1):1803. doi: 10.1186/s12889-022-14202-9. BMC Public Health. 2022. PMID: 36138385 Free PMC article.
In the primary analysis, we used logistic regression models to estimate the adjusted (age, sex, and history of confirmed COVID-19) VE against symptomatic SARS-CoV-2 resulted in a referral to triage centre for three vaccines used in Russia: Gam-COVID-Vac, EpiVacCorona, and …
In the primary analysis, we used logistic regression models to estimate the adjusted (age, sex, and history of confirmed COVID-19) VE agains …
Longitudinal Randomized Cohort Study of SARS-CoV-2 Antibody Seroprevalence in the St. Petersburg Population.
Smirnov VS, Lyalina LV, Milichkina AM, Khamitova IV, Zueva EV, Ivanov VA, Zaguzov VS, Totolian AA. Smirnov VS, et al. Viruses. 2022 Apr 27;14(5):913. doi: 10.3390/v14050913. Viruses. 2022. PMID: 35632653 Free PMC article. Clinical Trial.
During the second year of monitoring, some volunteers were vaccinated with the GamCOVIDVac (84%) or EpiVacCorona (11.6%) vaccines approved in Russia. Statistical processing was carried out using Excel 2010. ...
During the second year of monitoring, some volunteers were vaccinated with the GamCOVIDVac (84%) or EpiVacCorona (11.6%) vaccines app …